BeOne Medicines (ONC) EBIT (2015 - 2026)

BeOne Medicines (ONC) has reported EBIT for 12 consecutive years, with $249.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBIT rose 2150.96% year-over-year to $249.9 million; the TTM figure through Mar 2026 stood at $685.9 million (up 331.93% YoY), while the FY2025 annual figure was $447.1 million, up 178.69% from the prior year.
• EBIT climbed to $249.9 million in Q1 2026 per ONC's latest filing, from $185.0 million in the prior quarter.
• Across five years, EBIT topped out at $249.9 million in Q1 2026 and bottomed at -$468.6 million in Q4 2022.
• Historically, EBIT has averaged -$168.7 million across 5 years, with a median of -$134.0 million in 2023.
• Annual changes were most pronounced in 2022 — EBIT tumbled 731.76% — and 2026, when it soared 2150.96%.
• BeOne Medicines' EBIT stood at -$468.6 million in 2022, then advanced by 18.1% to -$383.8 million in 2023, then jumped by 79.31% to -$79.4 million in 2024, then jumped by 332.97% to $185.0 million in 2025, then soared by 35.06% to $249.9 million in 2026.
• Business Quant data shows ONC's EBIT at $249.9 million in Q1 2026, $185.0 million in Q4 2025, and $163.1 million in Q3 2025.